NGL Fine-Chem Ltd
Company Profile
Business description
NGL Fine-Chem Ltd is an Indian company engaged in the pharmaceutical business. It is a manufacturer of pharmaceuticals and intermediates for use in veterinary and human health, catering to various companies to custom-manufacture pharmaceuticals. The company's product portfolio comprises animal health APIs such as homidium chloride, nitroxynil, clorsulon, decoquinate, fenbendazole, etc.; human health APIs such as nitazoxanide and atovaquone; drug intermediates and specialty chemicals; and finished dosage forms such as diminazene aceturate granules and homidium chloride tablets. Geographically, the group generates maximum revenue from the Asia-Pacific region, and the rest from India, Europe, the USA, and the rest of the world.
Contact
301, E Square, Subhash Road
Vile Parle (East)
MumbaiMH400057
INDT: +91 2240842222
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 March 2027
Employees
523
Stocks News & Analysis
stocks
Chart of the Week: CGT reform strengthens the case for dividend investing
stocks
Finding ASX opportunities in lofty market conditions
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,122.70 | 62.80 | -0.68% |
| CAC 40 | 8,408.27 | 50.51 | -0.60% |
| DAX 40 | 25,460.48 | 3.53 | -0.01% |
| Dow JONES (US) | 51,594.14 | 1,153.18 | -2.19% |
| FTSE 100 | 10,917.39 | 8.98 | 0.08% |
| HKSE | 25,847.18 | 39.26 | 0.15% |
| NASDAQ | 24,442.94 | 433.97 | -1.74% |
| Nikkei 225 | 61,867.43 | 433.24 | 0.71% |
| NZX 50 Index | 13,762.78 | 213.89 | -1.53% |
| S&P 500 | 7,316.15 | 112.63 | -1.52% |
| S&P/ASX 200 | 8,967.70 | 57.10 | -0.63% |
| SSE Composite Index | 3,798.71 | 29.76 | -0.78% |